PNGM Financial Statements From 2010 to 2024

PNGM Stock  USD 0.0001  0.00  0.00%   
Er Therapeutics financial statements provide useful quarterly and yearly information to potential Er Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Er Therapeutics financial statements helps investors assess Er Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Er Therapeutics' valuation are summarized below:
Market Capitalization
332.1 K
There are over thirty-seven available fundamental measures for Er Therapeutics, which can be analyzed over time and compared to other ratios. Self-guided Investors are advised to verify Er Therapeutics' latest fundamentals against the trend between 2010 and 2024 to make sure the company can sustain itself in the future.
Check Er Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Er Therapeutics' main balance sheet or income statement drivers, such as Discontinued Operations of 0.0, Interest Expense of 0.0 or Selling General Administrative of 205.2 K, as well as many indicators such as . PNGM financial statements analysis is a perfect complement when working with Er Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Er Therapeutics Correlation against competitors.
To learn how to invest in PNGM Stock, please use our How to Invest in Er Therapeutics guide.

Er Therapeutics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets283.4 K487.1 K391 K
Slightly volatile
Total Current Liabilities308.4 K616.4 K491.2 K
Pretty Stable
Accounts Payable387 K368.6 K307.5 K
Slightly volatile
Cash302318575
Slightly volatile
Total Liabilities308.4 K616.4 K491.2 K
Pretty Stable
Total Current Assets302318600
Slightly volatile
Common Stock48.1 K66.4 K54.8 K
Slightly volatile
Property Plant Equipment498.5 K474.8 K395.7 K
Slightly volatile

Er Therapeutics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative205.2 K331.3 K272.5 K
Slightly volatile
Total Operating Expenses230.5 K358 K295.1 K
Slightly volatile

Er Therapeutics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Sale Purchase Of Stock34.5 K21.1 K32.3 K
Slightly volatile
Net Borrowings41.2 K24.9 K23.8 K
Pretty Stable
Other Cashflows From Financing Activities13.4 K15 K16.4 K
Slightly volatile
Capital Expenditures82.2 K78.3 K65.3 K
Slightly volatile
Change To Operating Activities30.2 K28.8 K24.4 K
Slightly volatile
Total Cash From Financing Activities110.7 K98.2 K113.1 K
Slightly volatile
Change To Netincome129.8 K123.6 K103 K
Slightly volatile
Change To Liabilities88.5 K170.4 K136.5 K
Pretty Stable

About Er Therapeutics Financial Statements

Er Therapeutics investors utilize fundamental indicators, such as revenue or net income, to predict how PNGM Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Er Therapeutics is a strong investment it is important to analyze Er Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Er Therapeutics' future performance. For an informed investment choice regarding PNGM Stock, refer to the following important reports:
Check out the analysis of Er Therapeutics Correlation against competitors.
To learn how to invest in PNGM Stock, please use our How to Invest in Er Therapeutics guide.
You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Is Diversified Metals & Mining space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Er Therapeutics. If investors know PNGM will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Er Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Return On Assets
(0.95)
The market value of Er Therapeutics is measured differently than its book value, which is the value of PNGM that is recorded on the company's balance sheet. Investors also form their own opinion of Er Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Er Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Er Therapeutics' market value can be influenced by many factors that don't directly affect Er Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Er Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Er Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Er Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.